About the Authors
- Shaija Samuel
-
Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Puja Gaur
-
Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Fan Fan
-
Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Ling Xia
-
Affiliation Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Michael J. Gray
-
Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Nikolaos A. Dallas
-
Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Debashish Bose
-
Affiliation Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Cristian Rodriguez-Aguayo
-
Affiliation Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Gabriel Lopez-Berestein
-
Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Greg Plowman
-
Affiliation Tumor Biology and Angiogenesis, Genentech, Inc., South San Francisco, California, United States of America
- Anil Bagri
-
Affiliation Tumor Biology and Angiogenesis, Genentech, Inc., South San Francisco, California, United States of America
- Anil K. Sood
-
Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
- Lee M. Ellis
-
* E-mail: lellis@mdanderson.org
Affiliations Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, Center for RNA Interference and Non-Coding RNA, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America
Competing Interests
LE is a consultant to Genentech, Inc., who provided the NRP-2 antibodies, and to Roche. GP and AB were paid employees of Genentech at the time of the study. A patent application has been filed relating to the anti-NRP antibodies from Genentech that were used in this manuscript. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: SS LE. Performed the experiments: SS PG FF LX MG ND DB. Analyzed the data: SS LE. Contributed reagents/materials/analysis tools: SS CR-A GL-B AS GP AB. Wrote the paper: SS LE.